158 related articles for article (PubMed ID: 32527950)
41. Nanoparticle-mediated targeting of autoantigen peptide to cross-presenting liver sinusoidal endothelial cells protects from CD8 T-cell-driven autoimmune cholangitis.
Carambia A; Gottwick C; Schwinge D; Stein S; Digigow R; Şeleci M; Mungalpara D; Heine M; Schuran FA; Corban C; Lohse AW; Schramm C; Heeren J; Herkel J
Immunology; 2021 Apr; 162(4):452-463. PubMed ID: 33346377
[TBL] [Abstract][Full Text] [Related]
42. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen.
Sharabi AB; Nirschl CJ; Kochel CM; Nirschl TR; Francica BJ; Velarde E; Deweese TL; Drake CG
Cancer Immunol Res; 2015 Apr; 3(4):345-55. PubMed ID: 25527358
[TBL] [Abstract][Full Text] [Related]
43. Antigen-loaded Monocyte Administration and Flt3 Ligand Augment the Antitumor Efficacy of Immune Checkpoint Blockade in a Murine Melanoma Model.
D'Anniballe VM; Huang MN; Lueck BD; Nicholson LT; McFatridge I; Gunn MD
J Immunother; 2023 Nov-Dec 01; 46(9):333-340. PubMed ID: 37737688
[TBL] [Abstract][Full Text] [Related]
44. Expression of B7-H1 in inflammatory renal tubular epithelial cells.
Chen Y; Zhang J; Li J; Zou L; Zhao T; Tang Y; Wu Y
Nephron Exp Nephrol; 2006; 102(3-4):e81-92. PubMed ID: 16282703
[TBL] [Abstract][Full Text] [Related]
45. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
[TBL] [Abstract][Full Text] [Related]
46. Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells.
Ostrand-Rosenberg S; Horn LA; Alvarez JA
Cancer Immunol Immunother; 2015 Oct; 64(10):1287-93. PubMed ID: 25792524
[TBL] [Abstract][Full Text] [Related]
47. PD-1/PD-L1 Pathway Modulates Macrophage Susceptibility to Mycobacterium tuberculosis Specific CD8
Suarez GV; Melucci Ganzarain CDC; Vecchione MB; Trifone CA; Marín Franco JL; Genoula M; Moraña EJ; Balboa L; Quiroga MF
Sci Rep; 2019 Jan; 9(1):187. PubMed ID: 30655556
[TBL] [Abstract][Full Text] [Related]
48. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
[TBL] [Abstract][Full Text] [Related]
49. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
50. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
51. TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer.
Park BV; Freeman ZT; Ghasemzadeh A; Chattergoon MA; Rutebemberwa A; Steigner J; Winter ME; Huynh TV; Sebald SM; Lee SJ; Pan F; Pardoll DM; Cox AL
Cancer Discov; 2016 Dec; 6(12):1366-1381. PubMed ID: 27683557
[TBL] [Abstract][Full Text] [Related]
52. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
[TBL] [Abstract][Full Text] [Related]
53. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.
Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM
J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267
[TBL] [Abstract][Full Text] [Related]
54. Tumor endothelial cell-induced CD8
Sakano Y; Noda T; Kobayashi S; Sasaki K; Iwagami Y; Yamada D; Tomimaru Y; Akita H; Gotoh K; Takahashi H; Asaoka T; Tanemura M; Wada H; Doki Y; Eguchi H
Cancer Sci; 2022 May; 113(5):1625-1638. PubMed ID: 35289033
[TBL] [Abstract][Full Text] [Related]
55. Altered Binding of Tumor Antigenic Peptides to MHC Class I Affects CD8
Clancy-Thompson E; Devlin CA; Tyler PM; Servos MM; Ali LR; Ventre KS; Bhuiyan MA; Bruck PT; Birnbaum ME; Dougan SK
Cancer Immunol Res; 2018 Dec; 6(12):1524-1536. PubMed ID: 30352798
[TBL] [Abstract][Full Text] [Related]
56. IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation.
Caudana P; Núñez NG; De La Rochere P; Pinto A; Denizeau J; Alonso R; Niborski LL; Lantz O; Sedlik C; Piaggio E
Cancer Immunol Res; 2019 Mar; 7(3):443-457. PubMed ID: 30651291
[TBL] [Abstract][Full Text] [Related]
57. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.
Homet Moreno B; Zaretsky JM; Garcia-Diaz A; Tsoi J; Parisi G; Robert L; Meeth K; Ndoye A; Bosenberg M; Weeraratna AT; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Ribas A
Cancer Immunol Res; 2016 Oct; 4(10):845-857. PubMed ID: 27589875
[TBL] [Abstract][Full Text] [Related]
58. Cutting edge: identification of autoreactive CD4+ and CD8+ T cell subsets resistant to PD-1 pathway blockade.
Pauken KE; Nelson CE; Martinov T; Spanier JA; Heffernan JR; Sahli NL; Quarnstrom CF; Osum KC; Schenkel JM; Jenkins MK; Blazar BR; Vezys V; Fife BT
J Immunol; 2015 Apr; 194(8):3551-3555. PubMed ID: 25769925
[TBL] [Abstract][Full Text] [Related]
59. Blockade of programmed death-1 in young (New Zealand black x New Zealand white)F1 mice promotes the activity of suppressive CD8+ T cells that protect from lupus-like disease.
Wong M; La Cava A; Singh RP; Hahn BH
J Immunol; 2010 Dec; 185(11):6563-71. PubMed ID: 21041733
[TBL] [Abstract][Full Text] [Related]
60. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
